API – Commercial
| Sr. No. | Product Name | Therapeutic Category | Regulatory Status | ||
|---|---|---|---|---|---|
| Filed | Under Filing | DMF | |||
1 |
Acetazolamide | Anti-glaucoma / Diuretic |
|
|
|
2 |
Alogliptin Benzoate | Anti-diabetic |
|
||
3 |
Amiodarone Hydrochloride | Anti-arrhythmic |
|
|
|
4 |
Amisulpride | Anti-emetic / Anti-psychotic |
|
|
|
5 |
Apixaban | Anti-coagulant |
|
|
|
6 |
Azilsartan Medoxomil Potassium | Anti-hypertensive |
|
|
|
7 |
Brexpiprazole | Anti-psychotic |
|
||
8 |
Carbamazepine | Anti-convulsant |
|
|
|
9 |
Carvedilol | Anti-hypertensive |
|
|
|
10 |
Chlorothiazide | Diuretic |
|
|
|
11 |
Chlorthalidone | Anti-hypertensive |
|
|
|
12 |
Citicoline Sodium | Nootropic |
|
||
13 |
Dapagliflozin Propanediol Monohydrate | Anti-diabetic |
|
||
14 |
Deferasirox | Chelating Agent |
|
|
|
15 |
Eslicarbazepine Acetate | Anti-convulsant |
|
|
|
16 |
Hydrochlorothiazide | Diuretic |
|
|
|
17 |
Imeglimin Hydrochloride | Anti-diabetic |
|||
18 |
Irbesartan | Anti-hypertensive |
|
|
|
19 |
Lamotrigine | Anti-convulsant |
|
|
|
20 |
Lercanidipine | Anti-hypertensive |
|
|
|
21 |
Linagliptin | Anti-diabetic |
|
|
|
22 |
Mesalamine (Mesalazine) | Anti-inflammatory |
|
|
|
23 |
Metoprolol Succinate | Anti-hypertensive |
|
|
|
24 |
Metoprolol Tartrate | Anti-hypertensive |
|
|
|
25 |
Mirabegron | Treatment Of Over Active Bladder |
|
||
26 |
Olmesartan Medoxomil | Anti-hypertensive |
|
|
|
27 |
Ondansetron Hydrochloride | Anti-emetic |
|
||
28 |
Oxcarbazepine | Anti-convulsant |
|
|
|
29 |
Oxymetazoline Hydrochloride | Topical Nasopharyngeal |
|
|
|
30 |
Pregabalin | Anti-convulsant |
|
|
|
31 |
Rosuvastatin Calcium | Anti-hyperlipoproteinemic |
|
|
|
32 |
Saxagliptin | Anti-diabetic |
|
||
33 |
Telmisartan | Anti-hypertensive |
|
||
34 |
Ticagrelor | Prevention Of Thrombotic Events |
|
|
|
35 |
Vildagliptin | Anti-diabetic |
|
||
36 |
Xylometazoline Hydrochloride | Topical Nasopharyngeal |
|
|
|
USDMF
Assessed
USDMF
Filed
CEP
EDMF
NMPA
KFDA
MOG
Russia
ANVISA
Ready
DMF
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.